Medscape

Intramuscular Aripiprazole May Be Effective Against Acute Agitation in Psychosis

Oct. 13, 2004 (Stockholm) — The atypical antipsychotic aripiprazole (Abilify) is as effective as haloperidol and significantly more effective than placebo at treating acute agitation in psychotic ...
Business Wire

ABILIFY® (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available

In two studies in agitated patients with schizophrenia, ABILIFY® (aripiprazole) Injection and Haldol® (haloperidol) intramuscular, a common conventional antipsychotic frequently used for acutely ...
Monthly Prescribing Reference

Phase 3 Study of Aripiprazole Intramuscular Depot for the Maintenance Treatment of Schizophrenia

Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the ...
Business Wire

Clinical Study Shows Intramuscular Administration of Aripiprazole (ABILIFY(R)) Significantly Improves Acute Agitation in Patients With Schizophrenia

NEW YORK-- (BUSINESS WIRE)--Patients with schizophrenia, schizoaffective and schizophreniform disorders who received treatment with intramuscular (IM) administration of aripiprazole (ABILIFY (R)) ...
FiercePharma

U.S. FDA Approves Dual-Chamber Syringe for Abilify Maintena® (aripiprazole) Extended-Release Injectable Suspension for the Treatment of Schizophrenia

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...
Monthly Prescribing Reference

Results from First-of-Kind Abilify Maintena Study Announced

ABILIFY MAINTENA (aripiprazole) 300mg and 400mg ext-rel injectable suspension Otsuka and Lundbeck announced results from the first-of-its-kind study comparing the effectiveness of aripiprazole ...
The Globe and Mail

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or ...

Otsuka America Pharmaceutical, Inc. (Otsuka) and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ABILIFY ASIMTUFII ® (aripiprazole) ...
FiercePharma

Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY – ABILIFY for Extended–release Injectable Suspension, for Intramuscular Use – Indicated for Schizophrenia

ABILIFY extended–release injectable suspension, for intramuscular use, is administered to the patient just once every four weeks. It first became available to patients in the US in March 2013 and is ...
PharmiWeb

Abilify Maintena® 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia

Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months1 Windsor, United Kingdom/Valby, Denmark, 27 March 2024 – Otsuka Pharmaceutical ...
Yahoo Finance

Health Canada Approves Otsuka and Lundbeck's (Pr)ABILIFY ASIMTUFII® (aripiprazole), the First-and-Only, Once-Every-Two-Months, Long-Acting Injectable (LAI) Treatment for ...

MONTREAL, Jan. 20, 2025 /CNW/ - Otsuka Pharmaceutical Canada Inc. (Otsuka) and Lundbeck Canada Inc. (Lundbeck) announce that Health Canada has issued a Notice of Compliance for ABILIFY ASIMTUFII ® ...